ASH 2022 | Anti-CD47 antibodies for complex karyotype AML
Farhad Ravandi, MD, University of Texas MD Anderson Cancer Center, Houston, TX, speaks on the difficulties of treating patients with acute myeloid leukemia (AML) with a complex karyotype. Dr Ravandi believes that anti-CD47 antibodies, such as magrolimab could effective in this patient population, with investigations currently ongoing. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Xencor: Research Funding; Prelude: Research Funding; Astex/Taiho: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding; AstraZeneca: Consultancy; Amgen: Honoraria, Research Funding; Novartis: Consultancy; BMS/Celgene: Consultancy, Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Syos: Consultancy, Honoraria, Research Funding; Astellas: Consultancy, Honoraria, Research Funding; Biomea Fusion, Inc.: Research Funding.
